Reactivating PP2A by FTY720 as a Novel therapy for AML with C-KIT tyrosine kinase domain mutation
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reactivating PP2A by FTY720 as a Novel therapy for AML with C-KIT tyrosine kinase domain mutation
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 113, Issue 4, Pages 1314-1322
Publisher
Wiley
Online
2011-11-22
DOI
10.1002/jcb.24003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients
- (2011) P P Ruvolo et al. LEUKEMIA
- PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect
- (2011) I Cristóbal et al. LEUKEMIA
- KITmutations confer a distinct gene expression signature in core binding factor leukaemia
- (2010) Sonja C. Lück et al. BRITISH JOURNAL OF HAEMATOLOGY
- Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers
- (2010) K. G. Roberts et al. CANCER RESEARCH
- The D816V Mutation of c-Kit Circumvents a Requirement for Src Family Kinases in c-Kit Signal Transduction
- (2009) Jianmin Sun et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia
- (2009) N Gallay et al. LEUKEMIA
- Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms
- (2009) Jie Lu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical implications of c-Kit mutations in acute myelogenous leukemia
- (2009) Muriel Malaise et al. Current Hematologic Malignancy Reports
- Optimal induction and post-remission therapy for AML in first remission
- (2009) J. M. Rowe Hematology-American Society of Hematology Education Program
- The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit
- (2008) M. Pedersen et al. CELLULAR SIGNALLING
- Phase II Study of Dasatinib in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis
- (2008) S. Verstovsek et al. CLINICAL CANCER RESEARCH
- KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: Two novel mutations and selective occurrence in leukemia subtypes and age groups
- (2008) Narongrit Sritana et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Cooperating gene mutations in acute myeloid leukemia: a review of the literature
- (2008) A Renneville et al. LEUKEMIA
- A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: The AFR-15 trial
- (2008) Patrice Chevallier et al. LEUKEMIA RESEARCH
- Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KITD816V
- (2008) Celalettin Ustun et al. LEUKEMIA RESEARCH
- PP2A-Mediated Dephosphorylation of p107 Plays a Critical Role in Chondrocyte Cell Cycle Arrest by FGF
- (2008) Victoria Kolupaeva et al. PLoS One
- Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML
- (2007) Anjali S. Advani et al. LEUKEMIA RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now